Download PDF
Thromb Haemost 2006; 95(05): 915-916
DOI: 10.1160/TH05-12-0824
Letters to the Editor
Schattauer GmbH

Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS)

Søren R. Kristensen
1   Department of Clinical Biochemistry, Cardiovascular Research Center, Aalborg Hospital, Århus University Hospital, Aalborg
,
Bo Abrahamsen
2   Department of Endocrinology
,
Jonna Skov Madsen
3   Department of Clinical Biochemistry, Odense University Hospital, Odense C
,
Jørgen Gram
4   Department of Clinical Biochemistry, Ribe County Hospital, Esbjerg, Department for Thrombosis Research, University of Southern Denmark
,
Lars Rejnmark
5   Department of Endocrinology and Metabolism C, Aarhus Sygehus, Aarhus University Hospital, Aarhus
,
Bo Rud
6   Department of Osteoporosis Research, Hvidovre Hospital, Hvidovre; Denmark
,
Jørgen Jespersen
4   Department of Clinical Biochemistry, Ribe County Hospital, Esbjerg, Department for Thrombosis Research, University of Southern Denmark
› Author AffiliationsFinancial support: The Danish Osteoporosis Prevention Study is financially supported by grants from the Karen Elise Jensen Foundation and from Novo Nordisk Farmaka (Lyngby, Denmark). The present investigation was supported by grants from the Danish Research Council, the Danish Heart Foundation (98–1–61–22501; B. & O. Rüditz-Larsen forskningsfond), the Institute of Clinical Research Odense University, the Faculty of Health Sciences Odense University and Overlægerådets legat Odense University Hospital.
Further Information

Publication History

Received 27 December 2006

Accepted after revision 26 March 2006

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Daly E, Vessey MP, Hawkins MM. et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
    CrossrefPubMedGoogle Scholar
  • 2 Jick H, Derby LE, Myers MW. et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. lancet 1996; 348: 981-3.
    CrossrefPubMedGoogle Scholar
  • 3 Daly E, Vessey MP, Painter R. et al. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027.
    PubMedGoogle Scholar
  • 4 Grodstein F, Stampfer MJ, Goldhaber J. et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
    CrossrefPubMedGoogle Scholar
  • 5 Perez SGutthann, Garcia LARodriguez, Castellsague J. et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.
    CrossrefPubMedGoogle Scholar
  • 6 Grady D, Wenger NK, Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Int Med 2000; 132: 689-96.
    PubMedGoogle Scholar
  • 7 Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-33.
    CrossrefPubMedGoogle Scholar
  • 8 The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-12.
    CrossrefPubMedGoogle Scholar
  • 9 Høibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism. Thromb Haemost 1999; 1218-21.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Mosekilde L, Hermann AP, Beck-Nielsen H. et al. The Danish osteoporosis prevention study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 1999; 31: 207-19.
    CrossrefPubMedGoogle Scholar